Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hem/Onc > Chemotherapy > Flashcards

Chemotherapy Flashcards

1
Q

Bendamustine

A

Alkylating Agent
Treanda®, Bendeka®, Belrapzo®
CLL, indolent lymphomas (Hodgkins/NHL)
90 mg/m2 days 1 and 2 every 28 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Altretamine

A

Alkylating Agent
Hexalen capsules
Ovarian Cancer
removed from market

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Busulfan

A

Alkylating Agent

Busulfex® (16mg/kg) in combination with cyclophosphamide (120mg/kg) as a conditioning regimen prior to bone marrow or peripheral blood progenitor cell replacement for CML (BuCy)

Myleran® (PO) the palliative treatment of CML. 4-8 mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Carboplatin

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Carmustine

A

Alkylating Agent
BicNu (IV) or Gliadel wafer

150 to 200 mg/m2 intravenously every 6 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chlorambucil

A

Alkylating Agent
Leukeran (po)
CLL, Hodgkin’s and NH lymphomas

0.1 to 0.2 mg/kg/day as palliative treatment (not for curative intent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cisplatin

A

Curative Intent

Nephrotoxicity- hydration
Highly emetogenic
Ototoxicity
Accumulative Neuropathy

Metastatic Testicular cancer- 20 mg/m2
Metastatic Ovarian Cancer-
75 mg/m2 + cyclophosphamide
Bladder Cancer- 50-70 mg/m2
Broad Spectrum- many other uses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclophosphamide

A

Alkylating Agent

1 mg/kg to 5 mg/kg ONCE DAILY

HYDRATION to prevent renal toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Dacarbazine

A

Alkylating Agent
DTIC (IV)

metastatic malignant melanoma: 2-4.5 mg/kg/day x10 days every 4 weeks

Hodgkin’s disease:
150 mg/m2 x5 days every 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ifosfamide

A

Alkylating Agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lomustine

A

Alkylating Agent- Nitrosourea

Gleostine

Brain tumors
130 mg/m2 every 6 weeks

Hodgkins Lymphoma
80-100 mg/m2 in combination with chemo regimens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Mechlorethamine

A

Alkylating Agent
Original Nitrogen Mustard
Valchlor
mycosis fungoides-type cutaneous T-cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Melphalan

A

Alkylating Agent

Alkeran® tablets or IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oxaliplatin

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Temozolomide

A

Alkylating Agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thiotepa

A

Alkylating Agent
Thioplex®, TSPA

Adenocarcinoma of the Breast or Ovary: 0.3 - 0.4 mg/kg every 1-4 weeks

Malignant Effusions: 0.6 to 0.8 mg/kg intracavitary q 1-4 weeks

Superficial Papillary Carcinoma of the Urinary Bladder: 60 mg intravesicularly once weekly x4 weeks

TEPADINA- peds with beta thalassemia (with BuCy prior to SCT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Trabectedin

A

Alkylating Agent
YONDELIS
liposarcoma or leiomyosarcoma

1.5 mg/m2 administered as an intravenous infusion over 24 hours through a central venous line every 21 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Streptozocin

A

Nitrosourea
Zanosar® (IV)
Treatment of islet cell cancer of the pancreas

500 mg/m2 daily x5 days every 6 weeks
or
1000 mg/m2 weekly then escalated

RENAL TOXICITY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Azacitidine

A

Hypomethylating Agent (HMA)

MDS: 75 mg/m2 SQ or IV daily x7 days every 28 days

AML: Onureg (po) 300 mg daily on Days 1 through 14 of each 28-day cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

5-fluorouracil (5-FU)

A

Antimetabolite

Indications: GI / Pancreatic / Breast

Bolus: false RNA base pair-neutropenia

Infusion: inhibits thymidylate synthase epithelial (hand foot / diarrhea)

Leucovorin: ^ thym synth inhibition

DPD deficiency

FOLFOX / FOLFIRINOX +- bevacizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

6-mercaptopurine (6-MP)

A

Antimetabolite

ALL- part of combination chemotherapy maintenance regimen

1.5 mg/kg to 2.5 mg/kg orally once daily

TPMT and NUDT15 Deficiency - dose adjustments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Capecitabine

A

Antimetabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Cladribine

A

Pur Ole Hairy Leu
Antimetabolite- Purine Analogue
Leustatin (IV)
Hairy Cell Leukemia

continuous infusion for 7 consecutive days at a dose of 0.09 mg/kg/day.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Clofarabine

A

Antimetabolite
Purine Analogue
Clolar (IV)

pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL)

52 mg/m2 as an intravenous infusion over 2 hours daily for 5 consecutive days of a 28-day cycle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Cytarabine

A

Antimetabolite
Ara-C
Pyrimidine Analogue

Leukemias/Lymphomas

7 + 3 AML induction
HDAC AML consolidation
Hyper CVAD
FLAG-Ida

26
Q

Decitabine

A

Hypomethylating Agent
(inhibits DNA methyltransferase)

Dacogen, INQOVI (with cedazuridine)

MDS

20 mg/m2 daily x5 days every 28 days

27
Q

Floxuridine

A

Antimetabolite
Pyrimidine Analogue
FUDR (IV)

continuous regional intra-arterial infusion (hepatic)

palliative management of gastrointestinal adenocarcinoma metastatic to the liver

28
Q

Fludarabine

A

Antimetabolite
Purine Analogue
Fludara (IV)
CLL (FCR)

25 mg/m2 x5 days every 28 day cycle

29
Q

Gemcitabine

A

Gemzar (IV)

Ara-C of solid tumors

Breast gem (1250 mg/m²) + paclitaxel
Ovarian gem (1000)+ carboplatin
Pancreas- single agent (1000 mg/m²)
NSLC- gem (1000 mg/m²)+ cisplatin

30
Q

Methotrexate

A

Antimetabolite

31
Q

Nelarabine

A

Antimetabolite
Purine Analogue
Arronon (IV)

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

32
Q

Pemetrexed

A

Antimetabolite (anti-folate)
Alimta

Indications: NSCLC
In combination with pembrolizumab and a platinum containing therapy

500 mg/m2 every 21 day cycle

Short 10 min infusion- very well tolerated

Billion dollar subgroup analysis- Skagliatti paper- pref for adenocarcinoma

33
Q

Pentostatin

A

Antimetabolite
Purine Analogue
Nipent (IV)

Hairy cell leukemia (single-agent)
4 mg/m2 every other week

34
Q

Thioguanine

A

Antimetabolite 6-TG
Tabloid (po) 40 mg tablets

Indications:
AML
ALL

35
Q

Trifluridine/tipiracil

A

Antimetabolite
Pyrimidine analogue
Lonsurf (po)

36
Q

Pralatrexate

A

Antimetabolite- dihydrofolate reductase inhibitor
Folotyn (IV)

Indications: peripheral T-cell Lymphoma (PTCL)

30 mg/m2 weekly 6 weeks every 7 week cycle

37
Q

Hydroxyurea

A

Antimetabolite
Inhibits ribonucleotide reductase (RR)
Which halts synthesis of DNA
Myeloproliferative Neoplasms
Essential Thrombocythemia, Polycythemia Vera
CML

For Sickle Cell-> increases fetal Hgb

38
Q

Daunorubicin

A

Anthracycline

Cerubidine®

AML, APL, ALL

7+3

daunorubicin 45 mg/m2 IV on d 1, 2, and 3 and cytarabine 100 mg/m2/day x7 days

39
Q

Doxorubicin

A

Anthracycline
Adriamycin
Doxorubicin Liposomal

40
Q

Epirubicin

A

Anthracycline

EllenceTM

AC Breast Cancer

41
Q

Idarubicin

A

Anthracycline

Induction therapy for AML

12 mg/m2 daily for 3 days in combination with cytarabine 100 mg/m2 daily for 7 days (7 + 3 regimen)

FLAG-IDA

42
Q

Valrubicin

A

Anthracycline

Valstar ®

INTRAVESICAL therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder

800 mg administered intravesically once a week for six weeks

43
Q

Bleomycin

A

Anti-tumor Antibiotic
Blenoxane®
Hodgkins Lymphoma- ABVD
Testicular/Ovarian Cancer- BEP
Malignant Pleural Effusions
NO myelosuppression
PULM TOXICITY- Pulmonary Fibrosis

44
Q

Dactinomycin

A

Anti-tumor Antibiotic

Cosmegen®

Wilms Tumor / Rhabdomyosarcoma

Ewing Sarcoma / Metastatic Nonseminomatous Testicular Cancer

45
Q

Mitomycin-C

A

Anti-tumor Antibiotic
MTC
Vesicant**
IV or Intravesicularly (into the bladder)

46
Q

Mitoxantrone

A

Novantrone ® (Other Name: DHAD)
Anti-tumor Antibiotic
Topoisomerase II Inhibitor

Hormone-Refractory Prostate Cancer
12 to 14 mg/m2 every 21 days + steroids

Initial Therapy for ANLL (ie AML)
12 mg/m2 + cytarabine

CARDIOTOXICITY

47
Q

Irinotecan

A

Topoisomerase I Inhibitor
Camptosar

Irinotecan liposomal (Onivyde)
+ 5FU/LV for pancreatic cancer

48
Q

Topotecan

A

Topoisomerase I Inhibitor

Hycamtin® (PO or IV) 1 mg or 0.25 mg

CAPSULES ONLY indicated for Small Cell Lung Cancer
2.3 mg/m2/day PO daily x5 days every 21 day cycle

Ovarian Cancer and Small Cell Lung Cancer: 1.5 mg/m2 IV daily x5 days every 21 day cycle

Cervical Cancer: 0.75 mg/m2 IV on Days 1, 2, and 3, with cisplatin 50 mg/m2 on Day 1, of a 21-day cycle

49
Q

Etoposide

A

Topoisomerase II Inhibitor

VePesid capsules / VP-16

Refractory Testicular Tumors (BEP)- IV
50 to 100 mg/m 2/day on days 1 through 5

Small Cell Lung Cancer- IV or PO
35 mg/m 2/day for 4 days to 50 mg/m 2/day for 5 days

dose of CAPSULES is 2x the IV dose rounded to the nearest 50 mg

R-ICE for lymphomas

50
Q

Teniposide

A

Topoisomerase II Inhibitor

Vumon® VM-26

Induction therapy in childhood ALL

51
Q

Cabazitaxel

A

Taxane- Microtubule (mitotic) Inhibitor

Jevtana®

castrate resistant metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

52
Q

Docetaxel

A

Taxane- Microtubule (mitotic) Inhibitor

53
Q

Nab-paclitaxel

A

Taxane- Microtubule (mitotic) Inhibitor

54
Q

Paclitaxel

A

Taxane- Microtubule (mitotic) Inhibitor

55
Q

Vinblastine

A

Vinca Alkaloid- microtubule inhibitor

56
Q

Vincristine

A

Vinca Alkaloid- microtubule inhibitor (M Phase specific)

Oncovin®
Lymphomas/Leukemias

NO bone marrow suppression
Peripheral neuropathy

R-CHOP, hyper-CVAD, EPOCH

57
Q

Vincristine liposomal

A

Vinca Alkaloid- microtubule inhibitor

58
Q

Vinorelbine

A

Vinca Alkaloid- microtubule inhibitor
Navelbine®

first-line treatment of patients with locally advanced or metastatic NSCLC

25 mg/m2 weekly +
cisplatin 100 mg/m2 q 4 weeks

30 mg/m2 weekly +
cisplatin 120 mg/m2 q 6 weeks

30 mg/m2 single agent

59
Q

Tretinoin

A

Vitamin A derivative
Vesanoid, ATRA
Acute Promyelocytic Leukemia (APL)

induces cytodifferentiation and decreased proliferation of APL cells

60
Q

Arsenic trioxide

A

Trisenox (ATO)

DNA fragmentation and degradation of PML/RAR protein

acute promyelocytic leukemia (APL)
w/ the presence of the t(15;17) translocation or PML/RAR-alpha

61
Q

Asparaginase

A

Enzyme that breaks down aspargine
Oncaspar (pegylated)
IM or IV
ALL

62
Q

Gemtuzumab ozogamicin

A

Mylotarg®
Antibody Drug Conjugate (ADC)
CD-33
AML

Hem/Onc (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions